Cited by 432

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

Open access

Finberg, John P. M., Rabey, Jose M.·2016·Frontiers in Pharmacology

DOI 10.3389/fphar.2016.00340

Open this paper in CoChat — free account

Abstract

Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which substrates and inhibitor molecules are metabolized, or inhibit metabolism of substrates, respectively. Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clinical use has been limited by their side effect of potentiation of the cardiovascular effects of dietary amines ("cheese effect"). A number of reversible MAO-A inhibitors which are devoid of cheese effect have been described in the literature, but only one, moclobemide, is currently in clinical use. The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clinically in treatment of Parkinson's disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious. Modification of the pharmacokinetic characteristics of selegiline by transdermal administration has led to the development of a new drug form for treatment of depression. The clinical potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fphar.2016.00340

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002) · Nature Structural Biology · doi:10.1038/nsb732 · Cited by 644
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors
Son, S.-Y., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E., & Tsukihara, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710626105 · Cited by 623
Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs
Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., Edmondson, D. E., & Mattevi, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070677y · Cited by 607
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B
De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 527
Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons.
Levitt, P., Pintar, J. E., & Breakefield, X. O. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.20.6385 · Cited by 526
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications
Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G., & Shiekhattar, R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.004 · Cited by 438
The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
Birkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem
Westlund, K. N., Denney, R. M., Rose, R. M., & Abell, C. W. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90250-3 · Cited by 354
Antiparkinsonian Drugs: Inhibition of Dopamine Uptake in the Corpus Striatum as a Possible Mechanism of Action
Coyle, J. T., & Snyder, S. H. (1969) · Science · doi:10.1126/science.166.3907.899 · Cited by 348
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
Lees, A. J. (1995) · BMJ · doi:10.1136/bmj.311.7020.1602 · Cited by 346
Deprenyl is metabolized to methamphetamine and amphetamine in man.
Reynolds, G., Elsworth, J., Blau, K., Sandler, M., Lees, A., & Stern, G. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb00883.x · Cited by 285
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction
Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707430 · Cited by 276
Selegiline slows the progression of the symptoms of Parkinson disease
Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., & the Swedish Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000204007.46190.54 · Cited by 271
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release
Finberg, J. P. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.010 · Cited by 257
Self-citation
Neurotransmission: The autonomic and somatic motor nervous systems
Hoffman, B. B. (1996) · Medical Entomology and Zoology · Cited by 256
A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 248
Brain Monoamine Oxidase A Activity Predicts Trait Aggression
Alia-Klein, N., Goldstein, R. Z., Kriplani, A., Logan, J., Tomasi, D., Williams, B., Telang, F., Shumay, E., Biegon, A., Craig, I. W., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0925-08.2008 · Cited by 245
Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease
Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M. H., Chirilineau, D., Stocchi, F., Lucini, V., Giuliani, R., Forrest, E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25961 · Cited by 234
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
Shulman, K. I., Herrmann, N., & Walker, S. E. (2013) · CNS Drugs · doi:10.1007/s40263-013-0097-3 · Cited by 227
Clinical Applications of MAO-Inhibitors
Riederer, P., Lachenmayer, L., & Laux, G. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364775 · Cited by 222
MAO-inhibitors in Parkinson's Disease
Riederer, P., & Laux, G. (2011) · Experimental Neurobiology · doi:10.5607/en.2011.20.1.1 · Cited by 215
Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition
Zheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 214
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70073-4 · Cited by 212
Safinamide: From molecular targets to a new anti-Parkinson drug
Caccia, C., Maj, R., Calabresi, M., Maestroni, S., Faravelli, L., Curatolo, L., Salvati, P., & Fariello, R. G. (2006) · Neurology · doi:10.1212/wnl.67.7_suppl_2.s18 · Cited by 195
Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa
Rabey, J. M., Sagi, I., Huberman, M., Melamed, E., Korczyn, A., Giladi, N., Inzelberg, R., Djaldetti, R., Klein, C., & Berecz, G. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200011000-00005 · Cited by 178
Self-citation
A Controlled Study of the Antidepressant Efficacy and Side Effects of ( — )-Deprenyl: A Selective Monoamine Oxidase Inhibitor
Mann, J. J. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010047007 · Cited by 178
Selegiline as initial treatment in de novo parkinsonian patients
Myllylä, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1992) · Neurology · doi:10.1212/wnl.42.2.339 · Cited by 171
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170
Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol
Maruyama, W., Akao, Y., Youdim, M. B. H., Davis, B. A., & Naoi, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00448.x · Cited by 169
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
Tatton, W. G. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.171s · Cited by 166
Reduced Apoptosis after Nerve Growth Factor and Serum Withdrawal: Conversion of Tetrameric Glyceraldehyde-3-Phosphate Dehydrogenase to a Dimer
Carlile, G. W., Chalmers-Redman, R. M. E., Tatton, N. A., Pong, A., Borden, K. L. B., & Tatton, W. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26436-1 · Cited by 164
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression
Lotufo-Neto, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00075-x · Cited by 159
International Review of Neurobiology
(2011) · International review of neurobiology · doi:10.1016/b978-0-12-385198-7.00014-x · Cited by 157
Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 154
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
Waters, C., Sethi, K. D., Hauser, R. A., Molho, E., & Bertoni, J. M. (2004) · Movement Disorders · doi:10.1002/mds.20036 · Cited by 153
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease
Wang, L., Esteban, G., Ojima, M., Bautista‐Aguilera, Ó. M., Inokuchi, T., Moraleda, I., Iriepa, I., Samadi, A., Youdim, M. B. H., Romero, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.078 · Cited by 143
Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo
Lamensdorf, I., Youdim, M. B. H., & Finberg, J. P. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67041532.x · Cited by 132
Self-citation
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
Youdim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.08.023 · Cited by 128
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells
Akao, Y., Maruyama, W., Yi, H. L., Shamoto‐Nagai, M., Youdim, M. B. H., & Naoi, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00332-4 · Cited by 125
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease
Weinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J. P. M., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_10 · Cited by 124
Self-citation
Selective inhibitors of monoamine oxidase type B and the “cheese effect”
Finberg, J. P. M., & Gillman, P. K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00009-1 · Cited by 123
Self-citation
Ladostigil prevents gliosis, oxidative–nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats
Shoham, S., Bejar, C., Kovalev, E., Schorer-Apelbaum, D., & Weinstock, M. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.005 · Cited by 123
Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l ‐[11C]Deprenyl
Arnett, C. D., Fowler, J. S., MacGregor, R. R., Schlyer, D. J., Wolf, A. P., Långström, B., & Halldin, C. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb02895.x · Cited by 123
High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland, T., Cohen, R. M., Molchan, S. E., Lawlor, B. A., Mellow, A. M., Newhouse, P. A., Tariot, P. N., Mueller, E. A., & Murphy, D. L. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950080019003 · Cited by 118
A randomized, double‐blind, placebo‐controlled trial of safinamide as add‐on therapy in early Parkinson's disease patients
Stocchi, F., Borgohain, R., Onofrj, M., Schapira, A., Bhatt, M., Lucini, V., Giuliani, R., & Anand, R. (2012) · Movement Disorders · doi:10.1002/mds.23954 · Cited by 117
A molecular signature in blood identifies early Parkinson’s disease
Molochnikov, L., Rabey, J. M., Dobronevsky, E., Bonuccelli, U., Ceravolo, R., Frosini, D., Grünblatt, E., Riederer, P. F., Jacob, C., Aharon‐Peretz, J., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-26 · Cited by 116
Self-citation
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease
Churchyard, A., Mathias, C. J., Boonkongchuen, P., & Lees, A. J. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.2.228 · Cited by 111
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
Finberg, J. P. M., Takeshima, T., Johnston, J. M., et al. (1998) · Neuroreport · doi:10.1097/00001756-199803090-00026 · Cited by 106
Self-citation
SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa
Przuntek, H., Conrad, B., DICHGANS, J., Kraus, P. H., Krauseneck, P., Pergande, G., Rinne, U. K., Schimrigk, К., Schnitker, J., & Vogel, H. P. (1999) · European Journal of Neurology · doi:10.1111/j.1468-1331.1999.tb00007.x · Cited by 106
The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
Yogev‐Falach, M., Amit, T., Bar‐Am, O., Weinstock, M., & Youdim, M. B. H. (2002) · The FASEB Journal · doi:10.1096/fj.02-0198fje · Cited by 105
Improvement of motor function in early Parkinson disease by safinamide
Stocchi, F., Arnold, G., ONOFRJ, M. C., Kwieciński, H., Szczudlik, A., Thomas, A., Bonuccelli, U., Dijk, A. V., Cattaneo, C., Sala, P. G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000134672.44217.f7 · Cited by 105
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor
Maruyama, W., Weinstock, M., Youdim, M. B. H., Nagai, M., & Naoi, M. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00211-8 · Cited by 100
Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor
Thébault, J. J., Guillaume, M., & Levy, R. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.14.1295.43156 · Cited by 98
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
Ben‐Shlomo, Y., Churchyard, A., Head, J. A., Hurwitz, B., Overstall, P. W., Ockelford, J., & Lees, A. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1191 · Cited by 95
Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging
Bar‐Am, O., Amit, T., Kupershmidt, L., Aluf, Y., Mechlovich, D., Kabha, H., Danovich, L., Zurawski, V. R., Youdim, M. B. H., & Weinreb, O. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.026 · Cited by 91
Discoveries in Pharmacology
(2022) · Elsevier eBooks · doi:10.1016/c2020-0-02436-9 · Cited by 91
Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord
Westlund, K. N., Krakower, T. J., Kwan, S., et al. (1993) · Brain Research · doi:10.1016/0006-8993(93)91664-e · Cited by 84
Pharmacology of rasagiline (N-propargyl-1R-aminoindan).
Finberg, J. P. M., Lamensdorf, I., Weinstock, M., Schwartz, M., & Youdim, M. B. H. (1999) · PubMed · Cited by 79
Self-citation
Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl-2 Family Members with PKC Pathway
Weinreb, O., Amit, T., Bar‐Am, O., Chillag-Talmor, O., & Youdim, M. B. H. (2005) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2005.tb00043.x · Cited by 78
The pharmacology of selegiline
Magyar, K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00004-2 · Cited by 76
Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents
Hill, M. N., Ho, W.-S. V., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0131-7 · Cited by 75
Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
Akhondzadeh, S., Tavakolian, R., Davari-Ashtiani, R., Arabgol, F., & Amini‎, H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00117-9 · Cited by 75
A controlled trial of methylene blue in severe depressive illness
Naylor, G. J., Smith, A. H. W., & Connelly, P. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90194-6 · Cited by 75
Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [11C] Harmine Positron Emission Tomography Study
Kolla, N. J., Matthews, B. A., Wilson, A. A., Houle, S., Bagby, R. M., Links, P. S., Simpson, A. I. F., Hussain, A., & Meyer, J. H. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.106 · Cited by 74
Advances Pertaining to the Pharmacology and Interactions of Irreversible Nonselective Monoamine Oxidase Inhibitors
Gillman, P. K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820469ea · Cited by 74
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
Finberg, J. P. M., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00216-2 · Cited by 72
Self-citation
Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues
Harvey, B. H., Duvenhage, I., Viljoen, F. P., Scheepers, N., Malan, S. F., Wegener, G., Brink, C. B., & Petzer, J. P. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.037 · Cited by 70
Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
Bieck, P. R., & Antonin, K. H. (1988) · PubMed · Cited by 65
Neurorescuing effects of the GAPDH ligand CGP 3466B
Waldmeier, P. C., Boulton, A. A., Cools, A. R., et al. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_13 · Cited by 63
Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules
Azzaro, A. J., Ziemniak, J. A., Kemper, E. M., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007304779 · Cited by 63
Monoamine oxidase inhibitor antidepressants
Youdim, M. B. H., & Finberg, J. P. M. (1985) · Elsevier eBooks · doi:10.1016/b978-0-444-90350-1.50008-8 · Cited by 63
Self-citation
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Jenner, P. G., & Langston, J. W. (2011) · Movement Disorders · doi:10.1002/mds.23926 · Cited by 60
An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of mao A and B
Denney, R. M., & Denney, C. B. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90050-6 · Cited by 59
Oral Tyramine Pressor Test and the Safety of Monoamine Oxidase Inhibitor Drugs
Bieck, P. R., & Antonin, K. H. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808000-00002 · Cited by 57
In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
Freedman, N. M. T., Mishani, E., Krausz, Y., Weininger, J., Lester, H., Blaugrund, E., Ehrlich, D., & Chisin, R. (2005) · PubMed · Cited by 56
Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
Elkashef, A., Fudala, P., Gorgon, L., Li, S.-H., Kahn, R., Chiang, N., Vocci, F., Collins, J., Jones, K., Boardman, K., et al. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.010 · Cited by 54
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
Clarke, A., Johnson, E. S., Mallard, N., Corn, T. H., Johnston, A. E., Boyce, M. J., Warrington, S., & MacMahon, D. G. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0042-6 · Cited by 52
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease
Weinreb, O., Amit, T., Riederer, P. F., Youdim, M. B. H., & Mandel, S. A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00007-8 · Cited by 47
Monoamine oxidase A gene polymorphism and suicide: An association study and meta-analysis
Hung, C., Lung, F., Hung, T., Chong, M., Wu, C.-K., Wen, J.-K., & Lin, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.013 · Cited by 47
The contribution of amphetamine metabolites of (?)-deprenyl to its antiparkinsonian properties
Elsworth, J. D., Sandler, M., Lees, A. J., Ward, C. D., & Stern, G. M. (1982) · Journal of Neural Transmission · doi:10.1007/bf01249283 · Cited by 47
Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects
Azzaro, A. J., VanDenBerg, C. M., Blob, L. F., Kemper, E. M., Sharoky, M., Oren, D. A., & Campbell, B. J. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289852 · Cited by 45
Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues
Mawhinney, M., Cole, D., & Azzaro, A. J. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2003.tb02430.x · Cited by 43
Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial
Mohammadi, M. R., Ghanizadeh, A. J., Alaghband‐Rad, J., Tehranidoost, M., Mesgarpour, B., & Soori, H. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.418 · Cited by 40
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO‐B) Inhibitor Rasagiline
Goren, T., Adar, L., Sasson, N., & Weiss, Y. M. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010369674 · Cited by 40
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
Jankovic, J. J., Berkovich, E., Eyal, E., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.024 · Cited by 40
Increased L ‐ DOPA ‐derived dopamine following selective MAO ‐ A or ‐ B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation
Sader-Mazbar, O., Loboda, Y. V., Rabey, M. J., & Finberg, J. P. M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12349 · Cited by 37
Self-citation
Placebo-Controlled Study Examining Effects of Selegiline in Children with Attention-Deficit/Hyperactivity Disorder
Rubinstein, S., MALONE, M. A., Roberts, W., & Logan, W. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.404 · Cited by 37
Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research
Yaşar, S., Goldberg, J., & Goldberg, S. R. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7494-4_6 · Cited by 36
Efficacy of Tranylcypromine in Bipolar Depression: A Systematic Review
Heijnen, W. T. C. J., Fruyt, J. D., Wierdsma, A. I., Sienaert, P. A., & Birkenhäger, T. K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000409 · Cited by 33
Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task
Buccafusco, J. J., Terry, A. V., Goren, T., & Blaugrun, E. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00937-5 · Cited by 32
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice
Weinreb, O., Badinter, F., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.009 · Cited by 31
Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway
Aluf, Y., Vaya, J., Khatib, S., Loboda, Y., & Finberg, J. P. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.023 · Cited by 27
Self-citation
Withdrawal and Discontinuation Phenomena Associated with Tranylcypromine: A Systematic Review
Gahr, M. L., Schönfeldt‐Lecuona, C., Kölle, M. A., & Freudenmann, R. W. (2013) · Pharmacopsychiatry · doi:10.1055/s-0032-1333265 · Cited by 26
Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin
Todd, K. G., & Baker, G. B. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j34s38 · Cited by 25
Effects of a Tyramine-Enriched Meal on Blood Pressure Response in Healthy Male Volunteers Treated with Selegiline Transdermal System 6 mg/24 Hour
Blob, L. F., Sharoky, M., Campbell, B. J., Kemper, E. M., Gilmor, M. L., VanDenBerg, C. M., & Azzaro, A. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020496 · Cited by 25
Rasagiline
Schapira, A. H. V., Bate, G., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1803 · Cited by 24
Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
n, M. S.-R., Sáenz‐Farret, M., Miguel‐Puga, J. A., Micheli, F. E., & Arias-Carrión, Ó. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00071 · Cited by 22
Monoamine Oxidase Inhibitors Revisited: What You Should Know
Goldberg, J. F., & Thase, M. E. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12ac08299 · Cited by 19
Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice
Ho, M.-C., Cherng, C. G., Tsai, Y.-P. N., Chiang, C.-Y., Chuang, J., Kao, S.-F., & Yu, L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1524-5 · Cited by 19
Functional connectivity in prenatally stressed rats with and without maternal treatment with ladostigil, a brain‐selective monoamine oxidase inhibitor
Goelman, G., Ilinca, R., Zohar, I., & Weinstock, M. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12621 · Cited by 18
Ageing and Parkinson's disease.
Playfer, J. R. (2007) · PubMed · Cited by 13
Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule
Aluf, Y., Vaya, J., Khatib, S., & Finberg, J. P. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.006 · Cited by 13
Self-citation
Type a and b monoamine oxidase in glial cells in long-term culture
Yu, P. H., & Hertz, L. (1983) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(83)90046-5 · Cited by 13
Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice
Badinter, F., Amit, T., Bar‐Am, O., Youdim, M. B. H., & Weinreb, O. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.041 · Cited by 12
A Phase 1 Trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion
Harris, D. S., Everhart, T., Jacob, P., Lin, E. T., Mendelson, J. E., & Jones, R. T. (2009) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-9-13 · Cited by 9
Issues in Adherence to Treatment With Monoamine Oxidase Inhibitors and the Rate of Treatment Failure
Cohen, L. J., & Sclar, D. A. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11096su1c.05 · Cited by 8
Dose-limiting inhibition of acetylcholinesterase by ladostigil results from the rapid formation and fast hydrolysis of the drug–enzyme complex formed by its major metabolite, R-MCPAI
Moradov, D., Finkin-Groner, E., Bejar, C., Sunita, P., Schorer-Apelbaum, D., Barasch, D., Nemirovski, A., Cohen, M., & Weinstock, M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.01.017 · Cited by 7

Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances: Miniperspective
Reis, J., Gaspar, A., Milhazes, N., & Borges, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01720 · Cited by 414
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression
Pitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Kumar, S., Chowdhury, S., & Kumar, S. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0394-8 · Cited by 103
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32

See all 432

Authors: Finberg, J. P. M., & Rabey, J. M.
Venue: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Published: 2016-10-18
Volume: 7
Pages: 340-340
ISSN: 1663-9812 (ISSN-L)
DOI: 10.3389/fphar.2016.00340
OpenAlex: W2536500264
Cited by: 432
References: 121
FWCI: 15.66
Type: journal article
Language: en
Open access: gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources